Australia - engleză - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate, quantity: 28.1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000 - sildenafil is indicated for the treatment of patients with pulmonary arterial hypertension (pah) classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.,the efficacy of sildenafil has not been evaluated in patients currently on bosentan therapy.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate, quantity: 140.48 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - sildenafil is indicated for the treatment of erectile dysfunction in adult males.,it is not indicated for use by women.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate, quantity: 70.24 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - sildenafil is indicated for the treatment of erectile dysfunction in adult males.,it is not indicated for use by women.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate, quantity: 35.12 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; croscarmellose sodium; povidone; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - sildenafil is indicated for the treatment of erectile dysfunction in adult males.,it is not indicated for use by women.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

kaiser foundation hospitals - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg - sildenafil is indicated for the treatment of pulmonary arterial hypertension (who group i) in adults to improve exercise ability and delay clinical worsening. the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [see clinical studies (14)] . studies establishing effectiveness were short-term (12 to 16 weeks), included predominately patients with new york heart association (nyha) functional class ii–iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%). limitation of use : adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see clinical studies (14)] . sildenafil is contraindicated in patients with: - concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see warnings and precautions (5.2)] . - known hypersensitivity to sildenafil or any component of the tablet. hypersensitivity, inc

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg - sildenafil is indicated for the treatment of pulmonary arterial hypertension (who group i) in adults to improve exercise ability and delay clinical worsening. the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [see clinical studies (14)] . studies establishing effectiveness were short-term (12 to 16 weeks), included predominately patients with new york heart association (nyha) functional class ii–iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%). limitation of use: adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see clinical studies (14)] . sildenafil is contraindicated in patients with: - concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see warnings and precautions (5.2)] . - concomitant use of riociguat, a guanylate cyclase stimulator. pde5 inhibitors, including silde

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg - sildenafil is indicated for the treatment of pulmonary arterial hypertension (who group i) in adults to improve exercise ability and delay clinical worsening. the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [see clinical studies (14)] . studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with new york heart association (nyha) functional class ii–iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%). limitation of use: adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see clinical studies (14)] . sildenafil is contraindicated in patients with: - concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see wa

Australia - engleză - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sildenafil citrate -